ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Journey Medical Corporation

Journey Medical Corporation (DERM)

3.68
-0.21
(-5.40%)
At close: March 28 04:00PM
3.68
-0.21
( -5.40% )
After Hours: 05:07PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

DERM News

Official News Only

DERM Discussion

View Posts
Awl416 Awl416 2 days ago
Solid day
👍️0
MiamiGent MiamiGent 9 months ago
DERM having a good morning:

$1.9299 +0.3399 (+21.38%)

https://stockcharts.com/h-sc/ui?s=DERM

BRIEF-Journey Medical Corporation Expects Topline Results FromPhase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10
REUTERS 8:12 AM ET Jul-03-2023
July 3 (Reuters) - Journey Medical Corp (DERM.NaE):

* JOURNEY MEDICAL CORPORATION EXPECTS TOPLINE RESULTS FROM THE PHASE 3 CLINICAL TRIALS (MVOR-1 AND MVOR-2) EVALUATING DFD-29 (MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE CAPSULES, 40 MG) FOR THE TREATMENT OF PAPULOPUSTULAR ROSACEA TO BE ANNOUNCED WEEK OF JULY 10, 2023
👍️0
Covid19freak Covid19freak 10 months ago
$1.65 -Phase 3 results within days if positive this low floater could double or triple quickly

company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
👍️0
The Night Stalker The Night Stalker 10 months ago
nice pump
👍️0
bUrRpPPP! bUrRpPPP! 4 years ago
QBREXZA sales are a joke due to nasty side effects....patients not refilling...just not worth it...link for reviews

https://www.webmd.com/drugs/drugreview-175967-qbrexza-towelette.aspx
👍️0
bUrRpPPP! bUrRpPPP! 4 years ago
Derm...details of Roche deal is just horrible...link

https://www.fiercebiotech.com/biotech/roche-part-sale-mixed-bag-lebrikizumab-to-dermira
👍️0
bUrRpPPP! bUrRpPPP! 4 years ago
California dermatology biotech Dermira will take on exclusive worldwide rights to IL-13 monoclonal antibody lebrikizumab from Roche, although the Big Pharma holds on to its rights for the med in certain indications.

The complex deal could be worth more than $1 billion in biobucks: Drilling down into the numbers, Dermira will make a first payment of $80 million to Roche, with future payments worth $55 million coming next year.

But that’s not all, as Dermira will also need to cough up extra payments if the med hits certain milestones, made up of $40 million when Dermira’s first phase 3 clinical study is started, and up to $210 million when it hits regulatory and first commercial sale milestones “in certain territories."
Webinar
How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC
CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.
Register Now

And then there’s the big number: $1.025 billion, based on the “achievement of certain thresholds for net sales of lebrikizumab,” in indications other than interstitial lung disease, which Roche will be hanging on to.

And should it gain approval, Dermira will also be making royalty payments “representing percentages of net sales that range from the high single-digits to the high teens.”

This comes after a mixed bag of data for the med, as last February, Roche suffered a setback when it posted one win and one loss for identical phase 3 studies for lebrikizumab in asthma patients.

The side-by-side studies were designed to give Roche a solid foundation of data for the approval and marketing of the anti-inflammatory drug for a clearly defined patient population.

But while Lavolta I hit its primary endpoint on significantly cutting the rate of asthma exacerbations among patients selected on two key biomarkers for airway inflammation, levels of serum periostin or blood eosinophils, Lavolta II missed the exact same measure of efficacy.

Ironically, Dermira, which got off a $125 million IPO in 2014 and now has a market cap north of $1 billion, has seen a similar situation with its experimental sweat drug DRM04, which last summer passed one Phase 3 test, but narrowly missed its target on a second late-stage trial, although analysts believed this would still be good enough to gain an FDA approval.
👍️0
bUrRpPPP! bUrRpPPP! 4 years ago
Derm design phase 2 study is a joke...patients were required to use TCS twice daily ...OBJECTIVE:

We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment

https://www.ncbi.nlm.nih.gov/pubmed/29353026

METHODS:

A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients achieving Eczema Area and Severity Index (EASI)-50 at week 12.
RESULTS:

In total, 209 patients received the study drug. At week 12, significantly more patients achieved EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%); [/]patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50 compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and mostly mild or moderate.
LIMITATIONS:

Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety evaluations.
CONCLUSION:

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.
👍️0
ClayTrader ClayTrader 4 years ago
* * $DERM Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
CA CHASE CA CHASE 4 years ago
$DERM $9... $8.50.. HOW ABOUT $8 THEN $7.50

PHARMA TRASH $ANAB $DERM
👍️0
CA CHASE CA CHASE 4 years ago
$DERM ANOTHER PHARMA SPIKE ON HYPE / SHORT THIS POS, $9 TO $8.55

"YOU'RE THE NEXT CONTESTANT ON THE PRICE IS TOO HIGH!"

F-PHARMA
👍️0
CA CHASE CA CHASE 4 years ago
$DERM ALRIGHTY.. LET'S SHORT THIS POS :) $9... LOL TIMBERRRRRRRRRRRRRR

F-PHARMA
👍️0
ClayTrader ClayTrader 4 years ago
* * $DERM Video Chart 10-18-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
PennyStock Alert PennyStock Alert 5 years ago
we got comps
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share. She said in a note to investors that she expects the Spanish pharmaceutical company Almirall to exercise its European rights to lebrikizumab, a treatment of moderate-to-severe atopic dermatitis.
Koffler said she attributes a 40% share selloff of the company's stock since April to financing uncertainty and the "lackluster" performance of the prescription anticholinergi Qbrexza.

"We believe Dermira could be strategically attractive to dermatology-focused companies," Koffler wrote. "We believe there could be significant cost synergies associated with cutting Qbrexza SG&A (Selling, General and Administrative Expenses)."

Koffler said that "the chief risk to our thesis is that Almirall walks away from EU rights."

"If Almirall abandons the deal, it may discourage other strategic interest in lebrikizumab as well," she wrote. "In this case, it's possible that Dermira would need to develop lebrikizumab on its own and pursue multiple financing rounds in the future against a limited catalyst calendar over the next three years while we await lebrikizumab approval and launch. Based on the pending Dermavant IPO focused on a Phase III psoriasis biologic, we believe the category is still attractive to investors and strategics and we view this scenario as unlikely."
👍️0
NSX NSX 5 years ago
Gave back significant gain after the last news. Healthcare sector fears holding this one back.

NSX sell rating for now, but keep an eye on this one and the chart.
👍️0
BottomBounce BottomBounce 5 years ago
Dermira, Inc. $DERM https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc-300813883.html
👍️0
BottomBounce BottomBounce 5 years ago
$DERM https://www.barchart.com/story/news/load-more-stories/1125662/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Hi Clay..Maybe we can get an updated DERM chart after the close? thanks!
👍️0
NSX NSX 5 years ago
Excellent Clay. Thanks
👍️0
BottomBounce BottomBounce 5 years ago
$DERM Thinking about buying stock in Aurora Cannabis Inc., Dermira Inc., Nio Inc., Soleno Therapeutics Inc., or Worldpay, Inc.?
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc-300813883.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $DERM Video Chart 03-18-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
NSX NSX 5 years ago
$14.04 is break point
👍️0
NSX NSX 5 years ago
Did you see the conversion line on the 10 minutes shoot straight up over the base line....dear lord

next, look at the 30 minutes. If the same happens then load up for a quick gain

NSX
👍️0
NSX NSX 5 years ago
Look for the conversion line to cross up and over the base line on the 10 minute chart and in 20 minutes, the same on the 30 minute as confirmation of another 50% rise!

otherwise she drifts back to 12.23!!

watch closely and make money
👍️0
NSX NSX 5 years ago
I see a bullish rise even yet.....

the gap will fill at some point, but not today
👍️0
TheFinalCD TheFinalCD 5 years ago
11.15 DIP FROM 14.98

DERM
👍️0
TheFinalCD TheFinalCD 5 years ago
8-K OUT https://ih.advfn.com/stock-market/NASDAQ/dermira-inc-DERM/stock-news/79491262/current-report-filing-8-k

some big buying around $12 area

I sold 12.94





👍️0
TheFinalCD TheFinalCD 5 years ago
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

https://www.globenewswire.com/news-release/2019/03/18/1756186/0/en/Dermira-Announces-Positive-Topline-Results-from-Phase-2b-Study-of-Lebrikizumab-in-Patients-with-Atopic-Dermatitis.html
👍️0
Opti Mist Opti Mist 6 years ago
Very glad I sold yesterday at 10.26 for a modest gain. I will take a modest gain over a significant loss any day.

Opti
👍️0
Grandmasters Grandmasters 6 years ago
DERM 30% Returns from $10.00

Patience folks.
👍️0
Opti Mist Opti Mist 6 years ago
this was not a good week. Down 3-5% daily.

troubling.

Opti
👍️0
Opti Mist Opti Mist 6 years ago
Time for DERM to climb back above $10

Opti
👍️0
crudeoil24 crudeoil24 6 years ago
FDA > APPROVAL !!!!!
👍️0
crudeoil24 crudeoil24 6 years ago
Dermira's Qbrexza For Treatment Of Excessive Underarm Sweating Gets FDA Approval -- MarketWatch
7:10 am ET June 29, 2018 (MarketWatch)
Share
Print
Dermira Inc. (DERM) said Friday its Qbrexza cloth for topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating, was approved by the Food and Drug Administration. Qbrexza is indicated for adult and pediatric patients nine years of age and older. The biopharmaceutical company said the cause of primary axillary hyperhidrosis is unknown, but affects nearly 10 million people in the U.S. The company expects Qbrexza to be available nationwide in pharmacies beginning in October 2018. The stock is currently halted for news until 7:30 a.m. ET. It has tumbled 68% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF (IBB) has gained 1.1% and the S&P 500 has edged up 1.6%.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer

(END) Dow Jones Newswires

June 29, 2018 07:10 ET (11:10 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
👍️0
seppi08162 seppi08162 6 years ago
What is going on this morning....
👍️0
Ijohnrob Ijohnrob 6 years ago
Good luck, hopefully we start moving up soon
👍️0
girlfriend girlfriend 6 years ago
Added a few more DERM at 7.9
👍️0
girlfriend girlfriend 6 years ago
Added a few at 8.40 and 8.48 on selloff Friday. Good luck to us!
👍️0
Ijohnrob Ijohnrob 6 years ago
I think $12 is reasonable in short term. I’ll probably cash out soon, even though I think long term may go above $20 — good one to keep an eye on. Good luck
👍️0
girlfriend girlfriend 6 years ago
I am here too but sold half from mid 8’s yesterday. Hoping for 12 target to unload rest....good luck
👍️0
Ijohnrob Ijohnrob 6 years ago
Am I the only one here — got in 8.75 — this is going to continue up!!
👍️0
Ijohnrob Ijohnrob 6 years ago
BS
👍️0
girlfriend girlfriend 6 years ago
Link please....DERM not acting like he did so far

<Carl Icahn took stake today>


Thank you
👍️0
Biggeoff Biggeoff 6 years ago
Carl Icahn took stake today
👍️0
Juschilln Juschilln 6 years ago
You think?
👍️0
conix conix 6 years ago
This cat may be dead.
👍️0
$treet $inatra $treet $inatra 6 years ago
Huge Drop!! Monster GAP DOWN!!
👍️0
venturecapp venturecapp 8 years ago
Off the Radar Dermira Targets a Billion Dollar Opportunity http://marketexclusive.com/off-the-radar-dermira-targets-a-billion-dollar-opportunity/1678/
👍️0
stocktrademan stocktrademan 9 years ago
$DERM recent news/filings

bullish
ascending triangle breakout

## source: finance.yahoo.com

Mon, 14 Sep 2015 12:53:12 GMT ~ Is Dermira (DERM) Stock a Solid Choice Right Now?


read full: http://finance.yahoo.com/news/dermira-derm-stock-solid-choice-125312034.html
*********************************************************

Thu, 10 Sep 2015 20:29:11 GMT ~ Krispy Kreme, Palo Alto, Con-Way are big movers


read full: http://finance.yahoo.com/news/krispy-kreme-palo-alto-con-202911657.html
*********************************************************

Thu, 10 Sep 2015 11:46:01 GMT ~ Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting

[at noodls] - Animal Data Demonstrate Accumulation of DRM01 in Sebaceous Glands Following Topical Administration MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical ...

read full: http://www.noodls.com/view/BDF00D3317CD8D9CF81A97A29CEB9FDF597DE610
*********************************************************

Thu, 10 Sep 2015 11:30:00 GMT ~ Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting

[GlobeNewswire] - MENLO PARK, Calif. -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced ...

read full: http://finance.yahoo.com/news/skin-disposition-study-results-dermiras-113000301.html
*********************************************************

Thu, 03 Sep 2015 11:45:05 GMT ~ Dermira to Present Data for DRM01 Acne Program at 45th Annual ESDR Meeting

[at noodls] - Results of Skin Disposition Study to be Presented on September 10, 2015 MENLO PARK, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused ...

read full: http://www.noodls.com/view/5FD40BFB4F820381FA6F62CE984E441BEC0CA66B
*********************************************************

$DERM charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$DERM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DERM/company-info
Ticker: $DERM
OTC Market Place: Not Available
CIK code: not found
Company name: Dermira, Inc.
Incorporated In:
$DERM share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$DERM extra dd links

Company name: Dermira, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DERM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DERM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DERM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DERM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DERM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DERM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/news - http://finance.yahoo.com/q/h?s=DERM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DERM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DERM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DERM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DERM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DERM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DERM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DERM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DERM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DERM
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dermira%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dermira%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dermira%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DERM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DERM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DERM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DERM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DERM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DERM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DERM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DERM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DERM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DERM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DERM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DERM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DERM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DERM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DERM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DERM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DERM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DERM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DERM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DERM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DERM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DERM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DERM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DERM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DERM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DERM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DERM



$DERM DD Notes ~ http://www.ddnotesmaker.com/DERM
👍️0

Your Recent History

Delayed Upgrade Clock